DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for dysplasia of cervix — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleDysplasia of cervix maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for dysplasia of cervix is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
A 2025 guideline review notes that new diagnoses of cervical cancer fell between 1999 and 2019 in the United States, yet the disease still accounts for roughly 4000 deaths per year there. High-grade dysplasia — encompassing high-grade squamous intraepithelial lesions, cervical intraepithelial neoplasia 2–3, and adenocarcinoma in situ — carries a greater risk of progression to invasive carcinoma. The review concerns itself with surveillance after treatment for these high-grade lesions but does not report any survival or response rates, nor does it test a drug.
A 2023 review of background and precancerous cervical diseases emphasises that environmental, exogenous and modifying factors — trauma, inflammation, viral infection — play the most important role in their occurrence. The article discusses local immunity but provides no quantitative data on outcomes, no sample sizes, and no drug intervention.
A 2024 case report describes a 68-year-old postmenopausal woman found to have adenosquamous carcinoma of the cervix (ASCC) in a hysterectomy specimen removed for uterovaginal prolapse. ASCC is a rare, aggressive histologic subtype with both malignant glandular and squamous components. The report states that early detection and appropriate management are crucial for favourable outcomes, but it is a single case with no survival figures, no response rates, and no drug treatment.
What is still missing: no clinical trial has tested a repurposed drug for cervical dysplasia or carcinoma in these abstracts; there is no data on patient stratification by HPV status, immune markers, or histologic subtype; and no funding source is identified for such a trial.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Guideline-Concordant Surveillance After Treatment for High-Grade Cervical Dysplasia
Abstract(Abstracted from Obstet Gynecol 2025;145(5):461–468) New diagnoses of cervical cancer decreased between 1999 and 2019, but this disease is still correlated with 4000 deaths per year in the United States. High-grade dysplasia, which includes high-grade squamous intraepithelial lesions, cervical intraepithelial neoplasia 2–3, and adenocarcinoma in situ, presents a greater risk for disease progression to carcinoma of the cervix.
Zenodo (CERN European Organization for Nuclear Research) · 2023 · 0 citations · open access
THE STATE OF LOCAL IMMUNITY IN BACKGROUND DISEASES OF THE CERVIX
AbstractThe article is devoted to the modern understanding of the etiopathogenesis of background and precancerous diseases of the cervix. The most important role in the occurrence of background and precancerous diseases of the cervix is played by environmental factors, i.e. exogenous and modifying factors, which may include trauma, inflammation, viral infection.
SAR Journal of Pathology and Microbiology · 2024 · 0 citations · open access
Adenosquamous Carcinoma of the Cervix - An Incidental Finding in the Hysterectomy Specimen of a Postmenopausal Female
AbstractAdenosquamous carcinoma of the cervix (ASCC) is a rare malignant histologic subtype that has well-defined malignant glandular and squamous components that can be recognized without special stains. Authors, hereby, describe a case of ASCC in a 68-year-old post-menopausal female who underwent hysterectomy for uterovaginal prolapse. A diffusely infiltrating growth involving both the lips of the cervix was seen on gross examination. Sections from the growth showed both malignant glandular and squamous components. ASCCs are rare and aggressive tumors; hence early detection and appropriate management is crucial for achieving favorable clinical outcomes.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
